Jiří MAŠTÁLKA

General
Contact
Committees
Dossiers (40)
Bio
Amendments (119)
History
Links

Constituencies

Czech Republic Komunistická strana Čech a Moravy 2009/07/14 - 9999/12/31

Show earlier Constituencies...

Groups

GUE/NGL Treasurer Confederal Group of the European United Left - Nordic Green Left 2009/07/14 - 9999/12/31

Show earlier groups...

EP staff

Quaestor of European Parliament 2012/01/18 - 9999/12/31
Member of Quaestors 2012/01/18 - 9999/12/31
Member of Parliament's Bureau 2012/01/18 - 9999/12/31

Show earlier staff positions...

Committees

Role	Committee	Start	End
Member of	Committee on Legal Affairs	2012/01/19	9999/12/31
Substitute of	Committee on the Environment, Public Health and Food Safety	2012/01/19	9999/12/31

Show earlier commitees...

Role	Committee	Start	End
Member of	Committee on Legal Affairs	2009/07/16	2012/01/18
Substitute of	Committee on the Environment, Public Health and Food Safety	2009/07/16	2012/01/18
Member of	Committee on Employment and Social Affairs	2007/01/31	2009/07/13
Substitute of	Committee on the Environment, Public Health and Food Safety	2007/01/31	2009/07/13
Member of	Committee on Employment and Social Affairs	2007/01/15	2007/01/30
Substitute of	Committee on the Environment, Public Health and Food Safety	2007/01/15	2007/01/30
Member of	Committee on Employment and Social Affairs	2004/07/21	2007/01/14
Substitute of	Committee on the Environment, Public Health and Food Safety	2004/07/21	2007/01/14
Member of	Committee on Regional Policy, Transport and Tourism	2004/05/03	2004/07/19
Observer of	Committee on Regional Policy, Transport and Tourism	2003/05/15	2004/04/30
Member of	Committee on Regional Policy, Transport and Tourism	2004/05/03	2004/07/19
Member of	Committee on Employment and Social Affairs	2004/07/21	2007/01/14
Substitute of	Committee on the Environment, Public Health and Food Safety	2004/07/21	2007/01/14
Member of	Committee on Employment and Social Affairs	2007/01/15	2007/01/30
Substitute of	Committee on the Environment, Public Health and Food Safety	2007/01/15	2007/01/30
Member of	Committee on Employment and Social Affairs	2007/01/31	2009/07/13
Substitute of	Committee on the Environment, Public Health and Food Safety	2007/01/31	2009/07/13

Delegations

Role	Delegation	Start	End
Member of	Delegation to the Euronest Parliamentary Assembly	2009/09/16	9999/12/31
Member of	Delegation to the EU-Moldova Parliamentary Cooperation Committee	2009/09/16	9999/12/31

Show earlier delegations...

Role	Delegation	Start	End
Member of	Delegation to the EU-Moldova Parliamentary Cooperation Committee	2004/09/15	2009/07/13
Substitute of	Delegation for relations with the People's Republic of China	2007/03/14	2009/07/13
Substitute of	Delegation for relations with the People's Republic of China	2004/09/15	2007/03/13
Member of	Delegation to the EU-Moldova Parliamentary Cooperation Committee	2004/09/15	2009/07/13
Substitute of	Delegation for relations with the People's Republic of China	2004/09/15	2007/03/13
Substitute of	Delegation for relations with the People's Republic of China	2007/03/14	2009/07/13

Contact

Online

Mail
[javascript protected email address]

Brussels

Phone
+322 28 45905
Fax
+322 28 49905
Office
Bât. Altiero Spinelli 06F365
Full Address
- City
  Bruxelles/Brussel
- Zip
  B-1047
- Street
  60, rue Wiertz / Wiertzstraat 60

Strasbourg

Phone
+333 88 1 75905
Fax
+333 88 1 79905
Office
Bât. Louise Weiss T12046
Full Address
- City
  Strasbourg
- Zip
  CS 91024 - F-67070
- Street
  1, avenue du Président Robert Schuman

Postal

Evropský parlament
Rue Wiertz
Altiero Spinelli 06F365
B-1047 Brusel

Rapporteur

Shadow	2013/0089(COD)	Trade marks: approximation of the laws of the Member States. Recast
Shadow	2013/0088(COD)	European trade mark
Opinion	2013/0049(COD)	Consumer product safety
Shadow	2012/2294(INI)	Eco-innovation - Jobs and growth through environmental policy
Shadow	2012/2098(INI)	Corporate Social Responsibility: accountable, transparent and responsible business behaviour and sustainable growth
Shadow	2012/2024(INI)	Law of Administrative procedure of the European Union
Shadow	2012/0180(COD)	Collective management of copyright and related rights and multi-territorial licensing of rights in musical works for online uses in the internal market
Shadow	2012/0066(COD)	Placing on the market of portable batteries and accumulators containing cadmium intended for use in cordless power tools
Shadow	2012/0042(COD)	Greenhouse gas emissions and removals resulting from activities related to land use, land use change and forestry (LULUCF): accounting rules and action plans
Shadow	2012/0025(COD)	Pharmacovigilance: transparency and efficiency of the system. Directive
Shadow	2012/0023(COD)	Pharmacovigilance: transparency and efficiency of the system. Regulation
Shadow	2012/0007(COD)	Classification, packaging and labelling of dangerous preparations. Recast
Opinion	2011/2193(INI)	Voluntary and unpaid donation of tissues and cells
Shadow	2011/2181(INI)	Corporate governance framework for European companies
Shadow	2011/2046(INI)	14th company law directive on the cross-border transfer of company seats
Shadow	2011/2029(INI)	Better legislation, subsidiarity and proportionality and smart regulation
Shadow	2011/2027(INI)	Twenty-seventh annual report on monitoring the application of EU law (2009)
Shadow	2011/2006(INI)	Insolvency proceedings in the context of EU company law
Shadow	2011/0902(COD)	EU Civil Service Tribunal: temporary judges
Shadow	2011/0901B(COD)	Court of Justice: number of judges at the General Court (amend. Statute)
Shadow	2011/0901(COD)	Court of Justice: statute (amend. Protocol and Annex I)
Shadow	2011/0455(COD)	Staff Regulations of European Union officials: amendment of the Regulations
Shadow	2011/0421(COD)	Serious cross-border threats to health
Shadow	2011/0389(COD)	Statutory audits of annual accounts and consolidated accounts
Shadow	2011/0359(COD)	Statutory audit of public-interest entities: specific requirements
Shadow	2011/0308(COD)	Company law: annual financial statements, consolidated financial statements and related reports of certain types of undertakings
Shadow	2011/0284(COD)	Common European Sales Law
Shadow	2011/0135(COD)	Office for Harmonisation in the Internal Market (Trade Marks and Designs): tasks related to the protection of intellectual property rights
Shadow	2011/0130(COD)	Mutual recognition of protection measures in civil matters
Shadow	2011/0060(CNS)	Judicial cooperation in civil matters: jurisdiction, applicable law and recognition and enforcement of decisions regarding property consequences of registered partnerships
Shadow	2011/0059(CNS)	Judicial cooperation in civil matters: jurisdiction, applicable law and recognition and enforcement of decisions in matters of matrimonial property regimes
Shadow	2011/0038(COD)	Company law and corporate governance: interconnection of central, commercial and company registers
Shadow	2010/2016(INI)	Guaranteeing independent impact assessments
Shadow	2010/0383(COD)	Jurisdiction, recognition and enforcement of judgments in civil and commercial matters. Recast
Responsible	2009/0151(COD)	Waste statistics. Codification
Responsible	2009/0100(NLE)	Civil judicial cooperation: international recovery of child support and other forms of family maintenance. 2007 The Hague Convention
Responsible	2008/0009(COD)	Mergers of public limited liability companies (repeal. Directive 78/855/EEC). Codification
Opinion	2007/0020(COD)	Community statistics on public health and health and safety at work
Opinion	2005/0166(COD)	European Monitoring Centre for Drugs and Drug Addiction EMCDDA (recast Regulation (EEC) No 302/93)
Responsible	2004/2205(INI)	Promoting health and safety in the workplace

Born

1956/01/03 Sušice

Doctor of Medicine (General Medical Faculty, Kiev Medical Institute, 1979-1981); certificate of postgraduate study, grade one - internal medicine (1984); certificate of postgraduate study in cardiology (1989). Doctor (since 1981).
Member of the executive board of the central committee of KSČM (Communist Party of Bohemia and Moravia) (1995-1999). Chairman of the KSČM town committee for Plzeň City (1993-2003).
Member of Plzeň City Council (1994-1998). Member of the Federal Assembly of the Czechoslovak Federal Republic (1990-1992). Member of the Chamber of Deputies of the Parliament of the Czech Republic (since 1996). Vice-Chairman of the Committee for Social Policy and Health Care (2002-2004).
Observer at the European Parliament (2003-2004). Member of the Chamber of Deputies' delegation to the Council of Europe (since 2002).

Amendments

Amendments	Dossier
1	2008/0225(COD) Visas: third countries whose nationals are subject to or exempt from a visa requirement. Codification 2010/04/05 ENVI 1 amendments... Amendment 15 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 1 Regulation (EC) No 726/2004 Article 20b – paragraph 3 3. The Agency may object to the information submitted or parts thereof on grounds related to non-compliance with the provisions of Title VIIIa of Directive 2001/83/EC within 6120 days after receipt of the notification. If the Agency does not object within 6120 days, the information shall be deemed accepted and may be published. The marketing authorisation holder remains fully liable and responsible for the information provided in all cases. source: PE-441.030
27	2008/0256(COD) Medicinal products for human use: information on products subject to medical prescription 2010/05/25 ENVI 27 amendments... Amendment 30 # Jiří MAŠTÁLKA Proposal for a directive - amending act Recital 1 (1) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use establishes harmonised rules on the advertising of medicinal products for human use. In particular, it prohibits the advertising to the general public of medicinal products subject to medical prescription in order to protect public health. Amendment 62 # Jiří MAŠTÁLKA Proposal for a directive - amending act Recital 11 (11) In order to further ensure that marketing authorisation holders ~~disseminat~~make available only high-quality information and to distinguish non-promotional information from advertising, the types of information which may be ~~disseminated~~made available should be defined. It is appropriate to ~~allow~~clarify that marketing authorisation holders ~~to disseminat~~can make available the contents of the approved summaries of product characteristics and package leaflet~~, information that is compatible with those documents without going beyond their key elements, and other well-defined medicinal product- related information~~ and the public assessment reports. Amendment 80 # Jiří MAŠTÁLKA Proposal for a directive - amending act Recital 14 (14) Monitoring of information on prescription-only medicinal products should ensure that the information made available by marketing authorisation holders ~~only disseminate information~~ which is in compliance with Directive 2001/83/EC. Member States should adopt rules establishing effective and efficient monitoring mechanisms and allowing effective enforcement in cases of non-compliance and redress mechanisms for consumers. Monitoring should be based on the control of information prior to its dissemination, unless the ~~substance~~content of the information has already been agreed by the competent authorities ~~or if there is a different mechanism in place to ensure an equivalent level of adequate and effective monitoring~~. Amendment 85 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point – 1 a (new) Directive 2001/83/EC Article 86 – paragraph 1 – indent 7 a (new) (-1a) In Article 86 (1), the following indent shall be added: - drawing the general public's attention to a specific medicinal product or to a therapeutic class of medicinal products using therapeutic indications or signs and symptoms Amendment 104 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 2 Directive 2001/83/EC Article 88 – paragraph 4 (2) Article 88(4) is replaced by the following: “4. The prohibition set out in paragraph 1 shall not apply to vaccination campaigns and other campaigns in the interest of public health carried out by the industry and approved by the competent authorities of the Member States.”deleted Amendment 118 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 a – paragraph 1 1. Member States shall allow the marketing authorisation holder to ~~disseminate, either directly or indirectly through a third party,~~make available information to the general public or members thereof on authorised medicinal products subject to medical prescription provided that it is in accordance with the provisions of this Title. Such information shall not be considered advertising for the purposes of the application of Title VIII. Amendment 120 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 a – paragraph 2 2. This Title shall not cover the following: a) information relating to human health or diseases, provided that there is no reference, even indirect, to medicinal products; b) material provided by the marketing authorisation holder to healthcare professionals for distribution to patients.deleted Amendment 134 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 b – point a a) the summary of product characteristics, labelling and package leaflet of the medicinal product, as approved by the competent authorities, and the publicly accessible version of the assessment report drawn up by the competent authorities;. This information should be presented in the form of a list classified in alphabetical order or by therapeutic class and should not be accompanied by pictures or additional information to the exclusion of a statement regarding the availability of the same information in the website of the national competent authority or the European Medicines Agency. It should be available in a pdf format that faithfully represents the officially approved information drawn up by the competent authorities. Amendment 142 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 b – point b b) information which does not go beyond the elements of the summary of product characteristics, labelling and the package leaflet of the medicinal product, and the publicly accessible version of the assessment report drawn up by the competent authorities, but presents them in a different way;deleted Amendment 150 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 b – point c c) information ~~on the environmental impact of the medicinal product, prices and factual, informative announcements and reference material relating, for example, to pack changes or adverse- reaction warnings;~~relating to the disposal of unused medicinal product or waste derived from medicinal products as well as reference to any collection system in place. Amendment 158 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 b – point d d) medicinal product-related information about non-interventional scientific studies, or accompanying measures to prevention and medical treatment, or information which presents the medicinal product in the context of the condition to be prevented or treated.eleted Amendment 171 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 c – point a ~~a) health-related publications as defined by the Member State of publication, to the exclusion of unsolicited material actively distributed to the general public or members thereof;~~deleted Amendment 195 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 d – paragraph 2 – point c c) a statement indicating that the information is disseminated by a[name of the marketing authorisation holder]; Amendment 199 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 d – paragraph 2 – point d a (new) da) mail address or e-mail address allowing members of the general public to send comments to the national competent authorities; Amendment 203 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 d – paragraph 2 – point d b (new) (db) a statement indicating that members of the general public are encouraged to report negative side effects of prescription drugs to their doctor, pharmacist or to the national competent authorities. Amendment 215 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 e – Paragraph 1 1. Member States shall ensure that marketing authorisation holders' Internet websites for the dissemination of information on medicinal products subject to medical prescription faithfully reproduce the summary of product characteristics and the package leaflet of the medicinal products concerned in the official languages of the Member States where they are authorised. Amendment 222 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 (new) Directive 2001/83/EC Article 100e – paragraph 1 b (new) 1b. Member States shall make available on the website of the national competent authorities the approved and updated version of the summary of product characteristics, labelling and package leaflet of the medicinal product, the publicly accessible version of the assessment report and its summary where applicable. The website of the national competent authorities shall include a link to the Eudrapharm website. Amendment 243 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 g – paragraph 1 – subparagraph 3 The methods may include the voluntary control of information on medicinal products by ~~self-regulatory or~~ co- regulatory bodies and recourse to such bodies, if proceedings before such bodies are possible in addition to the judicial or administrative proceedings available in the Member States. Amendment 249 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 h – paragraph 1 – subparagraph 2 After registration of the Internet website, the information on a medicinal product contained therein may be provided by the marketing authorisation holder on other Internet websites throughout the Community if the contents are identical.deleted Amendment 257 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 h – paragraph 2 – subparagraph 1 2. Internet websites registered in accordance with paragraph 1 shall not contain links to other ~~marketing authorisation holder~~websites, with the exclusion of the competent authorities' websites, unless they have also been registered in accordance with that paragraph. Those websites shall identify the competent authority which granted the marketing authorisation and its website address. Amendment 260 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 h – paragraph 2 – subparagraph 2 Internet websites registered in accordance with paragraph 1 shall not allow the identification of members of the general public which have access to those websites or the appearance therein of unsolicited material actively distributed to the general public or members thereof. Those websites shall not contain web-TV, pod casts, video streaming or any other digital information format not strictly authorised in accordance with this Directive. Amendment 272 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 h – paragraph 3 3. The Member State where the Internet website has been registered shall be responsible for the monitoring of the contents disseminated on that website. The marketing authorisation holder shall remain fully responsible and liable for all the information it disseminates to the general public. Amendment 282 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 h – paragraph 5 a 5a. Member States shall require marketing authorization holder to add the following statements to the registered web site: - [the name of the marketing authorisation holder] is responsible for the information provided in this web site. - “If you believe that the information provided violate the law by being false, misleading or lacking in fair balance contact the national competent authority”. - “You are encouraged to report negative side effects of prescription drugs to your doctor, pharmacists or to the national competent authorities”. - “You can find information on prescription medicines authorised in the community on the following web site: [link to Eudrapharm]." Amendment 285 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 i – paragraph 1 – point c a (new) ca) the obligation to put in place complaint-handling systems and efficient redress mechanisms to deal with consumer complaints and to ensure fair compensation of victims. Amendment 286 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 i – paragraph 1 – subparagraph 1 a (new) Member States shall provide for the possibility to publish the name of a marketing authorisation holder responsible for disseminating non- compliant information on a medicinal product. Amendment 290 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 j – point c c) supply the authorities or bodies responsible for monitoring information on medicinal products with the information, the financial resources and assistance they require to carry out their responsibilities; Amendment 293 # Jiří MAŠTÁLKA Proposal for a directive - amending act Article 1 – point 5 Directive 2001/83/EC Article 100 k Information on homeopathic and herbal medicinal products referred to in Article 14(1) that have been classified as prescription-only shall be subject to the provisions of this Title. source: PE-441.215
9	2008/0257(COD) Medicinal products for human use: pharmacovigilance of products [amend. Regulations (EC) No 726/2004 (Community procedures) and (EC) No 1394/2007] 2010/01/03 ENVI 9 amendments... Amendment 17 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Recital 4 (4) The main tasks of the Agency in the area of pharmacovigilance laid down in Regulation (EC) No 726/2004 should be maintained and further developed, in particular as regards the management of the Community pharmacovigilance database and data-processing network (hereinafter referred to as 'the Eudravigilance database') ~~and~~, the coordination of safety announcements by the Member States. and the provision of information regarding safety issues to the public. Or. en Justification Amendment 18 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Recital 5 (5) In order to allow all competent authorities to receive and access, at the same time, pharmacovigilance information for medicinal products for human use authorised in the ~~Community~~Union, and share it, the Eudravigilance database should be maintained and strengthened as the single point of receipt of such information. Member States should therefore not impose on marketing authorisation holders any additional reporting requirements. Instead, the Eudravigilance database should simultaneously notify the relevant Member States of reports submitted by market authorisation holders. In order to ensure the high quality of information, Member States should support the development of national and regional pharmacovigilance centres' expertise. National competent authorities should collect the reports from these centres and should then transfer data to Eudravigilance database. The database should be fully accessible to the Member States, the Agency and the Commission, and accessible to an appropriate extent to marketing authorisation holders and the public. Amendment 26 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Recital 11 ~~(11)~~ In order to protect public health, there should be adequate funding of activities related to pharmacovigilance by the Agency. Provision should be made to allow adequate funding for pharmacovigilance activities through the collection of fees charged to marketing authorisation holders. The management of those collected funds should be under a permanent control of the Management Board in order to guarantee the independence of the Agency. Amendment 43 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 11 Regulation EC/726/2004 Article 24 – paragraph 2 – subparagraphs 3 a (new) The Agency shall work together with organisations representing health professionals, patients and consumers to define “the appropriate level of access”. Amendment 50 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 11 Regulation EC/726/2004 Article 26 – point 2 (2) a ~~summary of each meeting~~gendas for meetings, records of meetings, accompanied by decisions taken, details of votes and explanations of votes, including minority opinions of the committees referred to in points (a) and (aa) of Article 56(1) of this Regulation and the coordination group as regards pharmacovigilance activities; Amendment 52 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 11 Regulation EC/726/2004 Article 26 – point 3 (3) risk management systems for medicinal products authorised in accordance with this Regulation, with an explanation of how to operate them; Amendment 54 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 11 Regulation EC/726/2004 Article 26 – point 6 (6) information about how to report suspected adverse reactions to medicinal products and standard forms for their ~~web- based~~ reporting by patients and health-care professionals; Amendment 55 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 11 Regulation EC/726/2004 Article 26 – point 8 (8) a synopsis of protocols and public abstracts of results as regards post authorisation safety studies conducted in more than one Member State and referred to in Articles 107o and 107q of Directive 2001/83/EC; Amendment 57 # Jiří MAŠTÁLKA Proposal for a regulation – amending act Article 1 – point 11 Regulation EC/726/2004 Article 27 – paragraph 1 1. The Agency shall monitor selected medical literature for reports of suspected adverse reactions to medicinal products for human use containing certain active substances. It shall publish the list of active substances being monitored and the publications subject to this monitoring. The Agency shall monitor all medical literature for reports of suspected adverse reactions to medicinal products for human use containing well-established active substances. source: PE-438.413
14	2008/0260(COD) Medicinal products for human use: pharmacovigilance of products (amend. Directive 2001/83/EC, Community code) 2010/03/15 ENVI 14 amendments... Amendment 46 # Jiří MAŠTÁLKA Proposal for a directive – amending act Recital 10 (10) ~~In order to make it possible for the healthcare professionals an~~Within five years of the entry into force of this Directive, the Commission shall, following consultations with organisations representing patients, consumers and healthcare professionals, Member States and other interested parties, presents to ~~identify easily the most relevant information about the medicines they use,~~the European Parliament and the Council an assessment report regarding the readability of the summar~~y of the~~ies of product characteristics and the package leaflet ~~should include a concise section on the key information about the medicinal product and information how to minimize its risks and maximize its benefit~~s. Following analysis of the above data, the Commission shall, if appropriate, put forward proposal to improve the layout and the content of the summaries of product characteristics and of the package leaflet to ensure they are a valuable source of information for the general public and healthcare professionals. Amendment 56 # Jiří MAŠTÁLKA Proposal for a directive – amending act Recital 17 (17) ~~To further increase the coordination of resources between the Member States~~Each Member State should be responsible for the detection and follow- up of adverse events occurring on its territory. To further increase the level of expertise on pharmacovigilance, Member States should be ~~authorised to delegate certain pharmacovigil~~encouraged to organise training and regular exchancge ~~tasks to another Member Stat~~of information and expertise. Amendment 59 # Jiří MAŠTÁLKA Proposal for a directive – amending act Recital 18 (18) In order to simplify the reporting of suspected adverse reactions the marketing authorisation holders should report those reactions only to the Member States and the Member States should report those reactions ondirectly to the Community pharmacovigilance database and data- processing network referred to in Article 57(1)(d) of Regulation (EC) No 726/2004 (hereinafter ‘the Eudravigilance database’). Any change in the national database should be immediately and automatically reflected in the Eudravigilance database. The Eudravingilance database and the national database should be fully interoperable. Amendment 61 # Jiří MAŠTÁLKA Proposal for a directive – amending act Recital 19 (19) In order to increase the level of transparency on the processes of pharmacovigilance, the Member States should create and maintain medicines safety web-portals. To the same end, the marketing authorisation holders should ~~provide~~submit to the authorities ~~with prior warning about safety announcements~~safety announcements for prior authorisation and the authorities should provide each other with such a warning. Amendment 68 # Jiří MAŠTÁLKA Proposal for a directive – amending act Recital 28 (28) In order to protect public health, there should be adequate funding of activities related to pharmacovigilance by the national competent authorities. It should be possible to ensure adequate funding for pharmacovigilance activities through the collection of fees. However, the management of those collected funds should be under the permanent control of the national competent authorities in order to guarantee their independence. Amendment 134 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 9 Directive 2001/83/EC Article 22 In exceptional circumstances and following consultation with the applicant, the authorisation may be granted subject to a requirement for the applicant to ~~meet certain condition~~introduce specific procedures, in particular concerning the safety of the medicinal product, notification to the ~~national~~ competent authorities of any incident relating to its use, and action to be taken. This authorisation may be granted ~~only when the applicant can show that he is unable to provide comprehensive data on the efficacy and safety of the medicinal product under normal conditions of use,~~ for objective, verifiable reasons and must be based on one of the grounds set out in Annex I to Directive 2001/83/EC. Continuation of the authorisation shall be linked to the annual reassessment of these conditions.” Amendment 165 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 20 Directive 2001/83/EC Article 65 – point g 20. In Article 65, the following point (g) is added: “(g) the summary of the essential information necessary to use the medicine safely and effectively provided for in Article 11(3a) and Article 59(1)(aa).”deleted Amendment 171 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 102 – paragraph 1 – point 1 (1) take all appropriate measures to encourage patients, doctors, pharmacists and other health-care professionals to report suspected adverse reactions to the national competent authority ~~or the marketing author~~. Those measures shall include training for health professionals and for patients and a public information campaign for patients. Patients’ organisation s shoulder be involved in providing information and training to patients and in developing public information campaigns in cooperation with regulatory bodies. Amendment 182 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 102 – paragraph 1 – point 1 a (new) (1a) facilitate direct patient reporting through the provision of alternative reporting formats (email, telephone, fax and letter) in addition to web-based formats; Amendment 195 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 103 A Member State may delegate any of the tasks entrusted to it under this Title to another Member State subject to a written agreement of the latter. The delegating Member State shall inform the Commission, the Agency and all other Member States of the delegation in writing. The delegating Member State and the Agency shall make that information public.deleted Amendment 206 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 105 – paragraph 2 ~~The first paragraph shall not preclude the collection of fees to be paid by marketing authorisation holders for the carrying out of those activities by the national competent authorities.~~deleted Amendment 209 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 106 Each Member State shall set up and maintain a national medicines web-portal including a dedicated medicine safety web- p~~ortal~~age which shall be linked to the European medicines safety web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004. By means of the national medicines ~~safety~~ web-portals, the Member States shall make public at least the following: (1) the leaflets of the medicines available on the national market in the national language (and where applicable the link to the EMEA EudraPharm database), (2) the summary of the product characteristics and any conditions established in accordance with Articles 21a, 22 and 22a, together with any deadlines for their fulfilment, for each medicinal product which they have authorised, and (3) the assessment report. By means of the national medicines web- pages, the Member States shall make public at least the following: (1) risk management systems for medicinal products authorised in accordance with this Directive; (2) the list of medicinal products under intensive monitoring referred to in Article 23 of Regulation (EC) No 726/2004; (3) web-based structured forms for the reporting of suspected adverse reactions by healthcare professionals and patients based on the forms referred to in Article 25 of Regulation (EC) No 726/2004; (4) agendas for meetings of the pharmacovigilance committee and records of its meetings, accompanied by decisions taken, details of votes and explanations of votes, including minority opinions. Amendment 224 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 107 – point 2 2. The marketing authorisation holders m~~ay not refuse~~ust forward to the national competent authorities any reports of suspected adverse reactions received from patients and health-care professionals within 7 days following the receipt of the report. The marketing authorisation holder must inform the patient and health-care professional that their report has been forwarded to the competent authorities who will be in charge of the follow up. Member States shall, as appropriate, involve patients and health-care professionals in the follow up of any reports they receive. The national competent authorities may not refuse any reports of suspected adverse reactions received via post, telephone, fax or in electronic~~ally~~ format from patients and health-care professionals. Amendment 230 # Jiří MAŠTÁLKA Proposal for a directive – amending act Article 1 – point 21 Directive 2001/83/EC Article 107 – paragraph 4 Member States shall access reports on adverse reactions through the Eudravigilance database and shall assess the quality of the data received from marketing authorisation holders. They shall, as appropriate, involve patients and health-care professionals in the follow up of any reports they receive and request follow up of such reports to be conducted by the marketing authorisation holders. The marketing authorisation holders shall be required to report any follow up information received to the Eudravigilance database. source: PE-438.412
15	2010/2089(INI) Reducing health inequalities in the EU 2010/12/14 ENVI 9 amendments... Amendment 24 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Recital C a (new) Ca. whereas climate change is expected to result in a number of potential health impacts through increased frequency of extreme weather events such as heat waves and floods, through changing patterns of infectious disease, and via increased exposure to UV radiation; whereas not all EU countries are equally prepared to address these challenges, Amendment 36 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Recital F F. whereas rates of morbidity are usually higher among those in lower educational, occupational and income groups and substantial inequalities are also found in the prevalence of most specific diseases, including heart diseases, mental illness, and most specific forms of disability, Amendment 46 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Recital H H. whereas health inequalities are due to differences between population groups in a wide range of factors which affect health, including: living conditions; health-related behaviours and nutrition habits; education, occupation and income; health care, disease prevention and health promotion services; and public policies influencing the quantity, quality ~~and~~ distribution of and access to these factors, Amendment 52 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Recital H d (new) Hd. whereas people living in remote and insular areas continue to have limited access to prompt and high -quality healthcare, Amendment 53 # Bairbre de BRÚN, Jiří MAŠTÁLKA Motion for a resolution Recital H e (new) He. whereas patients leaving with chronic diseases or conditions form a specific group subject to inequalities in access to diagnosis and care, social and other support services, and are subject to vulnerabilities including financial strain, access to employment, social discrimination and stigma, Amendment 60 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Recital J a (new) Ja. whereas the middle- and long-term effects of EU states' increased indebtedness will have a very serious effect in particular on public sectors jobs and publicly organised and/or publicly subsidised social- health-, and care services, Amendment 78 # Bairbre de BRÚN, Jiří MAŠTÁLKA Motion for a resolution Paragraph 2 2. Stresses that attention must focus on the whole social gradient, with particular attention to be given to the needs of people in poverty, disadvantaged migrant and ethnic minority groups, people with disabilities, ~~elderly~~patients diagnosed with chronic diseases or conditions, older people and children living in poverty; Amendment 89 # Bairbre de BRÚN, Jiří MAŠTÁLKA Motion for a resolution Paragraph 2 e (new) 2e. Calls on the Commission and Member States to promote the consideration of functional age instead of chronological age as a means of assessing patients’ healthcare needs and access to treatment, particularly in older patients; Amendment 93 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Paragraph 3 3. Underlines that the economic and financial crisis and of the austerity measures undertaken by Member States, in particular on the supply side, may lead to a reduction in the level of funding for public health and health and long-term care services as a result of budget cuts and lower tax revenues, while the demand for health and long-term care services may increase as a result of a combination of factors that contribute to the deterioration of the health status among the general population; source: PE-454.502 2011/10/01 ENVI 6 amendments... Amendment 101 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Paragraph 4 4. Calls on the Council to evaluate measures to mitigate the impact of the economic crisis and of the austerity measures undertaken by Member States on the health care sector, in particular in the following areas: investing in health infrastructure, public health, health promotion and disease prevention, optimising funding for the health care sector, restructuring and reorganising the health care system; Amendment 122 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Paragraph 7 7. Calls on the Member States to promote policies aiming at ensuring healthy life conditions for all children, including actions to support pregnant women and parents; calls on the Member States to fully implement existing legislation on the protection of pregnant women at the workplace; Amendment 148 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Paragraph 9 a (new) 9a. Calls on the Member States to support a ‘local care approach’ and to ensure the provision of integrated healthcare, accessible at a local or regional level, enabling patients to be better supported in their own local and social environment; Amendment 151 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Paragraph 10 10. CRegrets the lack of ambition within the Europe 2020 strategy as regards to reducing health inequalities in the EU; calls on the Council and the Commission to give greater recognition within the Europe 2020 strategy to the fact that health and well-being are key to fighting exclusion and to include indicators stratified by socio-economic status in the monitoring of the Europe 2020 strategy; Amendment 170 # Bairbre de BRÚN, Jiří MAŠTÁLKA Motion for a resolution Paragraph 12 12. Calls on the Commission to ensure that the reduction of health inequalities, isncluding the specific needs of older people, are fully addressed in the future initiative on healthy ageing; Amendment 190 # Jiří MAŠTÁLKA, Bairbre de BRÚN Motion for a resolution Paragraph 16 a (new) 16a. Underlines that equal access to care is a pillar of a welfare state model based on solidarity and equality, and that the future of the EU's economies and our welfare states to a large extent will be dependent upon how increasing care needs will be organised; highlights that care work in our societies today is an important part of both the formal and informal economy; where the majority of workers are women, many times without proper working conditions and/or security; calls on the Council and the Commission to address the care economy with an aim to improve working conditions and reinforce public service care provision and equal access to care for all; source: PE-454.655
1	2011/0105(COD) Export and import of hazardous chemicals. Recast 2011/11/18 ENVI 1 amendments... Amendment 61 # Jiří MAŠTÁLKA Proposal for a regulation Article 24 – paragraph 3 3. The Commission shall examine whether it is appropriate for the Agency to charge a fee for the services provided to exporters within five years of the date referred to in the second subparagraph of Article 33 and, if necessary, submit a relevant proposal.Deleted source: PE-475.973
1	2011/0228(COD) Food safety: computer databases for identification of bovine animals and swine 2012/02/15 ENVI 1 amendments... Amendment 5 # Jiří MAŠTÁLKA Proposal for a directive Article 1 Directive 64/432/EEC Article 14 – paragraph 3 – part C – point 1 – indent 8 – date of death ~~and~~or slaughter, source: PE-480.878
1	2011/0308(COD) Company law: annual financial statements, consolidated financial statements and related reports of certain types of undertakings 2012/09/05 JURI 1 amendments... Amendment 180 # Jiří MAŠTÁLKA Proposal for a directive Article 36 – paragraph 4 4. ‘Project’ is equivalent to ~~a specific operational reporting unit at the lowest level within the undertaking at which regular internal management reports are prepared to monitor its business~~extractive activities that are covered by a contract or legal agreement that gives rise to an obligation to make payments to a government. source: PE-489.397
1	2011/0421(COD) Serious cross-border threats to health 2012/09/17 ENVI 1 amendments... Amendment 72 # Jiří MAŠTÁLKA Proposal for a decision Article 4 – paragraph 4 4. Before adopting or reviewing their national preparedness plan, Member States shall ~~consult~~inform each other and the Commission in relation to the issues referred to in points (a) and (b) of paragraph 1. source: PE-496.383
18	2011/0455(COD) Staff Regulations of European Union officials: amendment of the Regulations 2012/03/20 JURI 18 amendments... Amendment 75 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 16 a (new) Staff Regulations Article 45 b (new) 16a. The following Article 45b shall be inserted after Article 45a: 'Article 45b An official in function group AST/SC may, from grade SC 2, be appointed to a post in function group AST, on condition that his periodical report referred to in Article 43 shows that he has actually carried out functions corresponding to the AST function group for at least two years. An official appointed to a post in function group AST on the basis of this Article shall be classified in a grade and step such that his remuneration is at least equal to that to which he would have been entitled in the AST/SC function group.'; Amendment 82 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 20 Staff Regulations Article 52 – point b – paragraph 1 (b) at his own request on the last day of the month in respect of which the request was submitted where he is at least 63 years of age or between 58 and 653 years of age and satisfies the requirements for immediate payment of a pension in accordance with Article 9 of Annex VIII. The second sentence of the second paragraph of Article 48 shall apply by analogy. Amendment 85 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 21 – point b Staff Regulations Article 55 – paragraph 2 – sentence 1 The normal working week shall range from 4037,5 to 420 hours, the hours of the working day to be determined by the appointing authority Amendment 87 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 21 – point d Staff Regulations Article 55 – paragraph 4 4. The appointing authority of each institution may introduce flexible working- time arrangements, after consulting the Staff Committee. Officials to whom the provisions of the second paragraph of Article 44 apply shall manage their working- time without resorting to such arrangements. Amendment 90 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 22 Staff Regulations Article 55 a 22. Article 55a shall be amended as follows: (a) Point (e) of the first subparagraph of paragraph 2 shall be replaced by the following: ‘(e) during the last three years before he reaches retirement age, but not before the age of 58’ (b) In the second subparagraph of paragraph 2, the words ‘, or as of the age of 55’ shall be replaced by ‘, or during the last three years before reaching retirement age, but not before the age of 58’;deleted Amendment 103 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 33 – point b Staff Regulations Article 72 – paragraphs 2 and 2a ~~(b) In paragraphs 2 and 2a the number ‘63’ shall be replaced by ‘65’;~~deleted Amendment 104 # Jiří MAŠTÁLKA Proposal for a regulation Article 1– point 36 Staff Regulations Article 77 – paragraphs 1 and 5 – Article 80 – paragraph 6 – Article 81 a – paragraph 1 – point d ~~36. In the first and fifth paragraphs of Article 77, in the sixth paragraph of Article 80 and in Article 81a(1)(d), the number ‘63’ shall be replaced by ‘65’;~~deleted Amendment 125 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 47 Staff Regulations Annex V – Article 7 – paragraph 1 – introductory wording To the annual leave of officials ~~entitled to the expatriation or foreign residence allowance~~ shall be added travelling time based on the geographical distance between the place of employment and the place of origin, calculated as follows: Amendment 135 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – paragraph 1 – point 47 Staff Regulations Annex V – Article 7 – paragraph 1 – indent 3 – ~~more than~~1201 to 12800 km: three days of home travelling time. Amendment 137 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 47 Staff Regulations Annex V – Article 7 – paragraph 1 – indent 3 a (new) – 1801 to 2400 km: four days of home travelling time Amendment 138 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 47 Staff Regulations Annex V – Article 7 – paragraph 1 – indent 3 b (new) – more than 2400 km: five days of home travelling time Amendment 143 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 50 – point a Staff Regulations Annex VIII – Article 5 ~~(a) In Article 5, the number ‘63’ shall be replaced by ‘65’‘;~~deleted Amendment 144 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 50 – point c – point i Staff Regulations Annex VIII – Article 9 ~~(i) The number ‘63’ shall be replaced by ‘65’;~~deleted Amendment 148 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 50 – point e Staff Regulations Annex VIII – Article 12 – paragraphs 1 and 2 ~~(e) In Article 12(1) and (2), the number ‘63’ shall be replaced by ‘65’;~~deleted Amendment 149 # Jiří MAŠTÁLKA Proposal for a regulation Article 1 – point 50 – point f Staff Regulations Annex VIII – Articles 15 and 18 a ~~(f) In Articles 15 and 18a, the number ‘63’ shall be replaced by ‘65’;~~deleted Amendment 181 # Jiří MAŠTÁLKA Proposal for a regulation Article 2 – point 14 – point a Conditions of Employment Article 34 – paragraphs 2 and 3 ~~(a) In the second and third paragraphs, the number ‘63’ shall be replaced by ‘65’;~~deleted Amendment 182 # Jiří MAŠTÁLKA Proposal for a regulation Article 2 – point 16 Conditions of Employment Article 37–paragraph 4 16. In the fourth paragraph of Article 37~~, the number ‘63’ shall be replaced by ‘65’, and~~ the words ‘Article 2(a), (c) or (d)’ shall be replaced by ‘Article 2 (a), (c), (d), (e) or (f)’; Amendment 183 # Jiří MAŠTÁLKA Proposal for a regulation Article 2 – point 19 Conditions of Employment Article 47– point a 19. Point (a) of Article 47 shall be replaced by the following: ‘at the end of the month in which the servant reaches the age of 65, or, on an exceptional basis, at the date fixed in accordance with the second subparagraph of Article 52(b) of the Staff Regulations; or’;deleted source: PE-483.851
21	2011/2013(INI) Policy options for progress towards a European contract law for consumers and businesses 2011/04/03 JURI 21 amendments... Amendment 2 # Jiří MAŠTÁLKA Motion for a resolution Recital A A. whereas the idea of the European contract law initiative, ~~which seeks to~~targeted at addressing internal market problems ~~created~~that might be created, inter alia, by divergent bodies of contract law, has been under discussion for many years, Amendment 8 # Jiří MAŠTÁLKA Motion for a resolution Recital D D. whereas, there are other major facctor~~ding to a Commission survey of 2008, three-quarters of retailers sell only domestically, and cross-border selling often takes place~~ s different from the existence of diverging rules of national consumer contract law that impede consumers to buy cross- border including cultural obstacles such as language, preference for physical shops, demographic composition of the population and the digital literacy; limited access to broadband; reliability of online traders; lack of choice of means of payment and discriminatory charges between the means offered; privacy concerns; post-sale services; complaint handling a ~~few Member States only1 ,~~nd redress; territorial limitations of intellectual property rights; anti-competitive business practices, etc Amendment 13 # Jiří MAŠTÁLKA Motion for a resolution Recital E E. whereas the application of foreign (consumer) law to cross-border transactions under the Rome-I Regulation* has been seen to entail considerable2 could entail transaction costs for businesses, in particular for SMEs, which have been estimated at €15 000 per business and per 1 UK Federation of Small Businesses, Position paper on Rome I (2007). 2 OJ L 177, 4.7.2008, p. 6. 3 UK Federation of Small Businesses, Position paper on Rome I (2007). Member State1, Amendment 15 # Jiří MAŠTÁLKA Motion for a resolution Recital F F. whereas such transaction costs are perceived as important obstacles to cross- border trade, as confirmed by 60 % of EU retailers interviewed in 20083 , and whereas 46 % said harmonised rules would help to increase cross-border sales, 1 UK Federation of Small Businesses, Position paper on Rome I (2007). 2 OJ L 177, 4.7.2008, p. 6. 3 Eurobarometer 224, 2008, p. 4.deleted Or. en Amendment 21 # Jiří MAŠTÁLKA Motion for a resolution Recital G G. whereas there is evidence that the online market remains fragmented: in a survey, 61 % of 10 964 test cross-border orders failed, inter alia because traders refused to serve the consumer's country1; whereas, on the other hand, cross-border shopping appears to increase consumers' chances of finding a cheaper offer2 and of finding products not available domestically online3, 1 COM(2009)0557, p. 5. 2 Ibid, p. 3. 3 Ibid, p. 5.deleted Amendment 27 # Jiří MAŠTÁLKA Motion for a resolution Recital G a (new) Ga. whereas the existing evidence does not permit to deduce that diverging national contract law represent a significant barrier to cross-border trade and therefore any measures in this field should be based on clear evidence that such a initiative would make a real difference which cannot be achieved through other less intrusive means, Amendment 41 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 2 2. Favours the option of ~~setting up~~a ‘toolbox’ that should be endorsed by an interinstitutional agreement; doubts that at the current stage an optional instrument (OI) adopted by means of a regulation~~; believes that such an OI could be complemented by a ‘toolbox’ that should be endorsed by means of an interinstitutional agreement~~ would be the appropriate means to address any of the perceived problems in cross- border trading ; Amendment 50 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 3 3. Believes that a ‘toolbox’ could possibly be put into practice step-by-step, starting as a Commission tool, and being converted, once agreed between the institutions, into a tool for the Union legislator; points out that any ‘toolbox’ ~~would provide the necessary legal backdrop and underpinning against which an OI could operate~~used for business-to- consumer contracts should be based on an assessment of the national mandatory rules of consumer protection within but also outside the existing consumer law acquis and should provide the necessary specificities of consumer contracts at a genuinely high level of protection; Amendment 55 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 4 4. Considers that an OI would generate European added value, in particular by ensuring legal certainty through the jurisdiction of the Court of Justice, providing at a stroke the potential to surmount both legal and linguistic barriers, as an OI would naturally be available in all EU languages;deleted Amendment 60 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 5 5. Sees a compelling practical advantage in the flexible and voluntary nature of an opt-in instrument; calls, however, on the Commission to include in any proposal for an OI a mechanism for regular monitoring and review, with the close involvement of all parties concerned;deleted Amendment 74 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 6 6. Believes that ~~both~~only business-to-business ~~and business-to-consumer~~ contracts shwould be covered~~; emphasise~~ by a potential European contract law instrument; considers that the level of consumer protection ~~would~~ needs to be very high, a~~s mandatory national provisions, including in the area of consumer law, would be replaced~~nd that it should not be designed to replace national mandatory provisions, in particular regarding consumer contract law; Amendment 82 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 7 7. ~~Sees no reason why an OI should not be~~Worries that an OI available ~~as an~~for opt-in both in cross-border and domestic situations~~, as this would have the advantages of simplicity and cost- saving, especially for the SME sector; believes, however,~~ or only cross-border situations, would further complicate the legal environment, especially for the SME sector and for consumers, whereas its domestic application could oblige consumers that do not want to buy cross- border to conclude a contract under a extraneous regime; believes, consequently that the effects of a domestic opt-in on national bodies of contract law ~~merit~~call for specific analysis and caution; Amendment 89 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 8 8. Acknowledges that e-commerce or distance-selling contracts account for an important share of cross-border transactions; ~~believes, however, that an OI should not be limited to these types of transaction;~~ Amendment 92 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 9 9. Believes that the scope of a ‘toolbox’ could be quite broad~~, whereas any OI should be limited to the core~~ and that its recommendations on consumer contract~~ual~~ law ~~issues~~should be based on a genuinely high level of protection; Amendment 99 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 10 10. Sees benefits in a~~n OI~~ "toolbox" for contract law containing specific provisions for the most frequent types of contract, in particular for the sale of goods and provision of services; reiterates its earlier call to ~~inclu~~consider insurance contracts ~~within the scope of the OI~~, believing that such an instrument could be particularly useful for small-scale insurance contracts; ~~points out that some specific issues in connection with which an OI might be beneficial have been raised, such as digital rights and beneficial ownership;~~but considers that, on the other hand, there might be a need to exclude certain types of complex public law contracts; Amendment 105 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 11 11. Notes that according to the re ~~seems to be a clear constituency among SMEs which is expecting benefits from an OI, with the caveat that it should be drawn up in a manner which makes it simple and attractive to use f~~sponses to the recent Commission consultation, many business and consumers organisations are highly sceptical about any alleged advantages of an OI but would support a~~ll parties~~ toolbox option; Amendment 109 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 12 12. Believes that ~~whilst an OI will have the effect of providing a single body of law, there~~other alternatives should be considered as wiell s~~till be a need to seek~~uch as the provision of standard terms and conditions of trade which can be produced in a simple and comprehensible form, available off- the-shelf for SMEs and consumers with some form of trust mark system to ensure consumer confidence and most importantly for business-to-consumer contracts, linked to an on-line alternative dispute mechanism; Amendment 113 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 13 13. Recalls that further work on cross- border alternative dispute resolution (ADR), in particular for SMEs and consumers, remains a priority~~, but emphasises that, if the parties use one body of law provided by an OI, ADR will be further facilitated~~; calls on the Commission to consider synergies when putting forward a proposal; Amendment 118 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 14 14. Suggests that ~~lack of confidence in~~the non-existence of functioning and efficient cross-border redress systems cshould be further tackled by a direct linkage between ~~the OI~~a potential European contract law initiative and the European Order for Payment Procedure and the European Small Claims Procedure; Amendment 120 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 15 15. Notes concerns that consumers seldom feel they have a choice with regard to contract terms and are confronted with a ‘take it or leave it’ situation; strongly believes that an attractive OI, by opening up business opportunities and strengthening competition, will actually broaden the overall choice available to consumers;deleted Amendment 127 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 17 17. Appreciates that both expert and stakeholder groups already have a varied geographical and sectoral background; believes that stakeholder contributions will become even more important once the consultation phase is over and if the legislative procedure as such, which w~~ill~~ould need to be as inclusive and transparent as possible, is launched; source: PE-460.697
2	2011/2148(INI) Towards a space strategy for the European Union that benefits its citizens 2011/06/10 ENVI 2 amendments... Amendment 2 # Jiří MAŠTÁLKA Draft opinion Paragraph 2 2. Underlines the importance of the space programmes Galileo and EGNOS, which are key to optimising the application of the space policy to ~~transport so as to~~ benefit European citizens; calls for a speedy development of these programmes ~~in order to harmonise the European single market~~; Amendment 4 # Carl SCHLYTER, Jiří MAŠTÁLKA Draft opinion Paragraph 3 3. Reaffirms the importance of GMES, the Earth observation system which can provide easily accessible information at the global level, acquiring and analysing information and extracting precise and useful data for observing the environment and assisting in environmental policy design, as well as those involved in civil protection following earthquakes, tsunamis or environmental disasters; observes that, in light of the ‘Europe 2020’ objectives, GMES is an essential resource in combating climate change at the global level; source: PE-473.827
5	2011/2193(INI) Voluntary and unpaid donation of tissues and cells 2012/11/04 JURI 5 amendments... Amendment 1 # Tadeusz ZWIEFKA, Jiří MAŠTÁLKA Draft opinion Recital A a (new) A a. whereas Article 3(2)(c) of the Charter of Fundamental Rights of the European Union contains a prohibition on making the human body and its parts as such a source of financial gain, Amendment 2 # Tadeusz ZWIEFKA, Jiří MAŠTÁLKA Draft opinion Recital D a (new) D a. whereas voluntary and unpaid tissue and cell donations contribute to high safety standards for tissues and cells and therefore to the protection of human health, Amendment 4 # Tadeusz ZWIEFKA, Jiří MAŠTÁLKA Draft opinion Paragraph 1 a (new) 1 a. Underlines that any commercialisation of human tissue and cells violates the principles of equity, respect for human rights and undermines the ethics of altruistic donation; Amendment 10 # Tadeusz ZWIEFKA, Jiří MAŠTÁLKA Draft opinion Paragraph 5 5. Calls on the Member States and the Commission to pursue the option of extending the principle that deceased potential donors are presumed to consent to donation provided that they have not stated otherwise during their lifetime; calls, nevertheless, on the Member States to actively promote, regardless of their national systems, the concept of the declaration of consent, as such a declaration is undeniable proof of a potential donor's decision; Amendment 11 # Tadeusz ZWIEFKA, Jiří MAŠTÁLKA Draft opinion Paragraph 5 a (new) 5 a. Calls on the Commission and the Member States to raise awareness among European citizens of the capacity of voluntary and unpaid tissue and cell donation to address the gap between demand and supply more effectively; source: PE-486.137
3	2011/2306(INI) Trade aspects of the Eastern partnership 2012/03/29 INTA 3 amendments... Amendment 11 # Jiří MAŠTÁLKA Motion for a resolution Recital E E. whereas in 2011 Armenia made significant progress towards fulfilling the key recommendations, and the launch of DCFTA negotiations ~~could therefore start in the foreseeable future~~was announced in February 2012; Amendment 62 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 18 18. Applauds the Armenian Government for stepping up its efforts to fulfil the key recommendations in 2011, which led to the ~~closing of 20 negotiating chapters~~launch of the DCFTA negotiations in February 2012; Amendment 66 # Jiří MAŠTÁLKA Motion for a resolution Paragraph 19 19. Encourages Armenia to continue its work with the same enthusiasm in order to be able to ~~meet all the conditions for starting~~swiftly conclude the DCFTA negotiations ~~in the coming months~~; source: PE-486.022

Jiří MAŠTÁLKA on

Activities

Term 7 14.07.2009 / ...

Term 6 20.07.2004 - 13.07.2009

All references link to europarl.eu

History

(these mark the time of scraping, not the official date of the change)

2013-05-03

Groups/0/Organization	changed	Old Confederal Group of the European United Left New Confederal Group of the European United Left - Nordic Green Left
Groups/0/role	changed	Old Nordic Green Left - Treasurer New Treasurer
active	changed	Old New True

2013-05-02

Committees/0/end	added	9999-12-31
Committees/0/start	added	2012-01-19
Committees/1	added	end 9999-12-31 committee_id ENVI start 2012-01-19 role Substitute abbr ENVI Organization Committee on the Environment, Public Health and Food Safety
Committees/2	added	end 2012-01-18 committee_id JURI start 2009-07-16 role Member abbr JURI Organization Committee on Legal Affairs
Committees/3	added	end 2012-01-18 committee_id ENVI start 2009-07-16 role Substitute abbr ENVI Organization Committee on the Environment, Public Health and Food Safety
Committees/4	added	end 2009-07-13 committee_id EMPL start 2007-01-31 role Member abbr EMPL Organization Committee on Employment and Social Affairs
Committees/5	added	end 2009-07-13 committee_id ENVI start 2007-01-31 role Substitute abbr ENVI Organization Committee on the Environment, Public Health and Food Safety
Committees/6	added	end 2007-01-30 committee_id EMPL start 2007-01-15 role Member abbr EMPL Organization Committee on Employment and Social Affairs
Committees/7	added	end 2007-01-30 committee_id ENVI start 2007-01-15 role Substitute abbr ENVI Organization Committee on the Environment, Public Health and Food Safety
Committees/8	added	end 2007-01-14 committee_id EMPL start 2004-07-21 role Member abbr EMPL Organization Committee on Employment and Social Affairs
Committees/9/end	added	2007-01-14
Committees/9/start	added	2004-07-21
Committees/10	added	Organization Committee on Regional Policy, Transport and Tourism end 2004-07-19 role Member abbr None start 2004-05-03
Committees/11	added	Organization Committee on Regional Policy, Transport and Tourism end 2004-04-30 role Observer abbr None start 2003-05-15
Constituencies/0/end	added	9999-12-31
Constituencies/1	added	party Komunistická strana Čech a Moravy end 2009-07-13 start 2004-07-20 country Czech Republic
Constituencies/2	added	party Komunistická strana Čech a Moravy end 2004-07-19 start 2004-05-01 country Czech Republic
Delegations/0/abbr	deleted	DEPA
Delegations/0/end	added	9999-12-31
Delegations/0/start	added	2009-09-16
Delegations/1	added	Organization Delegation to the EU-Moldova Parliamentary Cooperation Committee end 9999-12-31 role Member abbr None start 2009-09-16
Delegations/2/abbr	deleted	D-MD
Delegations/2/end	added	2009-07-13
Delegations/2/start	added	2004-09-15
Delegations/3	added	Organization Delegation for relations with the People's Republic of China end 2009-07-13 role Substitute abbr None start 2007-03-14
Delegations/4	added	Organization Delegation for relations with the People's Republic of China end 2007-03-13 role Substitute abbr None start 2004-09-15
Groups/0	added	Organization Confederal Group of the European United Left end 9999-12-31 role Nordic Green Left - Treasurer groupid GUE/NGL start 2009-07-14
Groups/1	added	Organization Confederal Group of the European United Left end 2009-07-13 role Nordic Green Left - groupid GUE/NGL start 2004-07-20
Groups/2	added	Organization Confederal Group of the European United Left/Nordic Green Left end 2004-07-19 role Member groupid GUE/NGL start 2004-05-01
Groups/3/Organization	changed	Old Confederal Group of the European United Left - Nordic Green Left New Confederal Group of the European United Left/Nordic Green Left
Groups/3/end	added	2004-04-30
Groups/3/role	changed	Old Treasurer New Observer
Groups/3/start	added	2003-04-23
RSS	added	http://www.europarl.europa.eu/rss/mep/jiri.mastalka/en.xml
Staff/0/abbr	deleted	QUE
Staff/0/end	added	9999-12-31
Staff/0/start	added	2012-01-18
Staff/1/abbr	deleted	BURO
Staff/1/end	added	9999-12-31
Staff/1/start	added	2012-01-18
Staff/2	added	Organization Quaestors end 2012-01-16 role Member abbr None start 2009-07-15
Staff/3	added	Organization Parliament's Bureau end 2012-01-16 role Member abbr None start 2009-07-15
active	changed	Old True New

2012-11-30

2012-11-05

2012-09-25

2012-04-02

2012-03-09

2012-03-08

2012-02-10

Committees/0	added	Organization Legal Affairs role Member abbr JURI committee_id JURI
Committees/0	deleted	end 2014-01-31 committee_id JURI start 2009-01-14 role Member abbr JURI Organization Legal Affairs
Committees/1	added	Organization Environment, Public Health and Food Safety role Substitute abbr ENVI committee_id ENVI
Committees/1	deleted	end 2014-01-31 committee_id ENVI start 2009-01-14 role Substitute abbr ENVI Organization Environment, Public Health and Food Safety
Constituencies/0	added	country Czech Republic start 2009-07-14 party Komunistická strana Čech a Moravy
Constituencies/0	deleted	country Czech Republic end 2014-01-31 party Komunistická strana Čech a Moravy start 2009-01-14
Delegations/0	added	Organization Delegation to the EU-Moldova Parliamentary Cooperation Committee role Member abbr D-MD
Delegations/0	deleted	start 2009-01-14 end 2014-01-31 role Member abbr D-MD Organization Delegation to the EU-Moldova Parliamentary Cooperation Committee
Delegations/1	added	Organization Delegation to the Euronest Parliamentary Assembly role Member abbr DEPA
Delegations/1	deleted	start 2009-01-14 end 2014-01-31 role Member abbr DEPA Organization Delegation to the Euronest Parliamentary Assembly
Groups/0	added	Organization Confederal Group of the European United Left - Nordic Green Left role Treasurer groupid GUE/NGL
Groups/0	deleted	Organization Confederal Group of the European United Left - Nordic Green Left end 2014-01-31 role Treasurer groupid GUE/NGL start 2009-01-14
Staff/0	added	Organization Parliament's Bureau role Member abbr BURO
Staff/0	deleted	start 2009-01-14 end 2014-01-31 role Member abbr BURO Organization Parliament's Bureau
Staff/1	added	Organization Quaestors role Member abbr QUE
Staff/1	deleted	start 2009-01-14 end 2014-01-31 role Member abbr QUE Organization Quaestors

2012-01-21

Addresses	added	Brussels Phone +322 28 45905 Fax +322 28 49905 Address Building Bât. Altiero Spinelli City Bruxelles/Brussel Office 06F365 Zip B-1047 building_code ASP Street 60, rue Wiertz / Wiertzstraat 60 Organization Parlement européen Postal Evropský parlament Rue Wiertz Altiero Spinelli 06F365 B-1047 Brusel Strasbourg Phone +333 88 1 75905 Fax +333 88 1 79905 Address Building Bât. Louise Weiss City Strasbourg Office T12046 building_code LOW Street 1, avenue du Président Robert Schuman Organization Parlement européen Zip2 F-67070 Zip1 CS 91024
Birth	added	date 1956-01-03 place Sušice
CV	added	Doctor of Medicine (General Medical Faculty, Kiev Medical Institute, 1979-1981); certificate of postgraduate study, grade one - internal medicine (1984); certificate of postgraduate study in cardiology (1989). Doctor (since 1981). Member of the executive board of the central committee of KSČM (Communist Party of Bohemia and Moravia) (1995-1999). Chairman of the KSČM town committee for Plzeň City (1993-2003). Member of Plzeň City Council (1994-1998). Member of the Federal Assembly of the Czechoslovak Federal Republic (1990-1992). Member of the Chamber of Deputies of the Parliament of the Czech Republic (since 1996). Vice-Chairman of the Committee for Social Policy and Health Care (2002-2004). Observer at the European Parliament (2003-2004). Member of the Chamber of Deputies' delegation to the Council of Europe (since 2002).
Committees	added	end 2014-01-31 committee_id JURI start 2009-01-14 role Member abbr JURI Organization Legal Affairs end 2014-01-31 committee_id ENVI start 2009-01-14 role Substitute abbr ENVI Organization Environment, Public Health and Food Safety
Constituencies	added	country Czech Republic end 2014-01-31 start 2009-01-14 party Komunistická strana Čech a Moravy
Delegations	added	start 2009-01-14 role Member end 2014-01-31 abbr D-MD Organization Delegation to the EU-Moldova Parliamentary Cooperation Committee start 2009-01-14 role Member end 2014-01-31 abbr DEPA Organization Delegation to the Euronest Parliamentary Assembly
Gender	added	M
Groups	added	Organization Confederal Group of the European United Left - Nordic Green Left role Treasurer end 2014-01-31 groupid GUE/NGL start 2009-01-14
Mail	added	jiri.mastalka@europarl.europa.eu
Name	added	familylc maštálka full Jiří MAŠTÁLKA sur Jiří family MAŠTÁLKA aliases MASTALKAJiri Jiri MASTALKA jirimastalka maštálkajiří JiříMAŠTÁLKA jiřímaštálka MASTALKA MAŠTÁLKA JiriMASTALKA MAŠTÁLKA Jiří MAŠTÁLKAJiří jiri mastalka MASTALKA Jiri mastalka mastalkajiri jiří maštálka mastalka jiri maštálka Jiří MAŠTÁLKA maštálka jiří
Photo	added	http://www.europarl.europa.eu/mepphoto/23704.jpg
RSS	added	http://www.europarl.europa.eu/rss/mep/jiri.mastalka/en.xml
Staff	added	start 2009-01-14 role Member end 2014-01-31 abbr BURO Organization Parliament's Bureau start 2009-01-14 role Member end 2014-01-31 abbr QUE Organization Quaestors
UserID	added	23704
active	added	True
assistants	added	accredited JACEK Jan SEDLACKOVA-DOHELSKA Jana

Committees/0/Organization	changed	Old Legal Affairs New Committee on Legal Affairs
Committees/1/Organization	changed	Old Environment, Public Health and Food Safety New Committee on the Environment, Public Health and Food Safety
Committees/1/committee_id	deleted	ENVI

Parltrack